Introduction
Almost 1 million of total hip arthoplasties (THA) are implanted worldwide annually. Prosthetic implants improve quality of life and relieve symptoms, but some of these benefits are time limited in many cases. 1 A prosthesis which presents loosening required revision surgery, which has a high morbidity and mortality rate, especially in elderly patients with comorbidities. 2 While sepsis, fracture and dislocation are relatively rare, prosthetic failure secondary to aseptic loosening has become increasingly more common. 3 Arising from aseptic inflammatory reactions to the prosthetic implants, aseptic loosening results in progressive bone loss and periprosthetic osteolysis, 4 accounting for 75.7% of all THA revisions. 5, 6 To try and identify preventive measures, possible biological, physical and biophysical factors have been investigated. At present, it is thought that susceptibility to aseptic loosening results from a combination of environmental and genetic factors. Environmental factors such as type of prosthesis, material, fixation method, implant design, surgical technique and postoperative sport activity level have been widely studied, 7, 8 and investigations on 'genetic factors' may well give a more definite answer to this issue. To date, the precise aetiology of aseptic loosening is still unclear. 9 Even though inflammatory cytokines trigger a chronic inflammatory status which, if untreated, may determine soft tissue and supporting bone damage, basic sciences studies are being increasingly aimed at better understanding the molecular aspects of aseptic loosening, without restricting them to investigate only traditional inflammatory patterns. 3, 4 
Genetic
The present review focuses on the genetic aspects of early and late aseptic loosening and osteolysis after THA implantation. Genetic polymorphisms are genetic variations that are considered biologically normal and can be found in at least 1% of the population. These variations may influence protein transcription, and contribute towards individual susceptibilities to certain pathological conditions. 10 The rapidly evolving evidence on genetic factors and occurrence of numerous common diseases has led to integrate human genomics into the practice of medicine and public health. 11 Identifying and characterizing associated risk or protective factors, genetic determinants could be helpful to better understand several aetiologic aspects of disease, and develop potential treatment strategies. Thousands of reports have described gene -environment and gene-gene interactions probably involved in the development of pathological status, 11, 12 but the current evidence of studies on gene -disease associations is limited by several methodological limitations. 13, 14 Several commentaries have been produced, and different recommendations have been proposed. Given these intrinsic methodological limitations, a set of guiding principles for reporting results of genetic association studies has been provided in a recently published statement, the STrengthening the REporting of Genetic Association studies (STREGA). 15 
Methods
A comprehensive search was performed combining the keywords 'aseptic loosening', 'gene', 'hip arthoplasty', 'genetics', 'loosening' with no limit regarding the year of publication. Medline, CINAHL, Googlescholar, Embase and Cochrane databases were accessed to search English, Spanish, French, Portuguese and Italian publications. The first electronic search identified 46 relevant abstracts of articles published in peer-reviewed journals. Full-text versions were obtained if the abstract did not allow one to include or exclude the study. The reference lists of all selected articles were reviewed by hand to identify articles not included at the electronic search. Studies detailing the genetic investigation of patients with aseptic loosening of hip prosthetic implants were selected, and their bibliographies thoroughly reviewed to identify further related articles. Biomechanical reports, studies on animals, cadavers, in vitro, case reports, literature reviews, technical notes, letters to editors and instructional course were excluded. Eleven studies published from 1998 to 2010 were considered relevant to our interest. Genetic data were extracted. Additionally, data concerning loosening imaging assessment, demographic features, body mass index (BMI), type of prosthesis, time from prosthesis to revision surgery and osteolysis-free survival time were extracted (Tables 1 and 2 ). The STREGA statement was used to assess reporting quality (Table 3) . This statement provides additions to 12 of the 22 items on the previously defined STROBE checklist. 15 The additions concern population stratification, genotyping errors, modelling haplotype variation, HardyWeinberg equilibrium, replication, selection of participants, rationale for choice of genes and variants, treatment effects in studying Mannose-binding lectin (MBL) 550 C/C; codon 54 G/G Femoral stem aseptic loosening was defined either by surgical findings, and radiographic criteria of Harris et al., or progressive endosteal cavitation across zones as described by Gruen et al. Acetabular loosening was confirmed either at the time of revision surgery or by using the criteria of Hodgkinson et al. [10] Well-fixed control THAs were defined as clinically asymptomatic for over 10 years with no radiographic features of aseptic loosening as described by Pachecho et al.
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Proteins, receptors and intracellular mediators
In a study on 57 German Caucasian patients undergoing revision surgery for aseptic loosening of a THA, Bachman et al. 16 investigated the T393C polymorphism of GNAS1, the gene coding for the stimulatory Gas subunit, an ubiquitously expressed cAMP-dependent G-protein contributing in different pathways to bone physiology and aseptic loosening pathophysiology. Gas and Gas/cAMP pathways are involved in parathyroid hormone (PTH)-mediated osteoblastogenesis, mediate bone disorders such as McCune-Albright syndrome and Albright hereditary osteodystrophy, and functional defects of osteoblasts, 17, 18 and regulate interleukin-6 (IL-6) activation in osteoblasts, 19 macrophages 20 and osteoclasts. 21 In female patients, time and median time to aseptic loosening were not significantly associated with single T393C genotypes. However, combined comparison of TC and CC genotypes with TT genotype revealed significantly longer time and median time to aseptic loosening in female TT carriers (P ¼ 0.022). In male patients, the CC genotype carriers had longer time and median time to loosening than TC and TT genotype patients (P ¼ 0.018, P ¼ 0.023). Compared with a reference group of T393 homozygous male individuals, heterozygous patients had a 6.25-fold lower risk with a hazard ratio of 0.160 (95% CI: 0.04-0.71; P ¼ 0.016), while male patients carrying the CC genotype showed a significant (more than 11-fold) lower risk of loosening, with a hazard ratio of 0.088 (95% CI: 0.02-0.50; P ¼ 0.006).
The association between mannose-binding lectin (MBL) deficiency associated with SNPs at codons 52 and 54 and at promoter positions -550 and -221 and the development of aseptic loosening or deep infection around THAs has been investigated in a case -control study of 312 patients. 22 MBL is a liver-derived serum protein, which increases during the acute-phase response to infection, takes part in the opsonization of bacteria and mediates complement activation. Acting as the complement component C1q and activator of the complement cascade, 18-3.98 ) and G/G genotype (P ¼ 0.027) were associated with aseptic failure. No statistically significant relationship was found between aseptic loosening and the promoter 221 or codon 52 SNPs. The C allele (P ¼ 0.01; OR ¼ 1.90; 95% CI ¼ 1.14 -3.16) and genotype C/C (P ¼ 0.05) for the 550 SNP were significantly more frequent among septic than control patients. Regarding the codon 54 SNP, the G/G genotype (P ¼ 0.05; OR ¼ 1.47; 95% CI ¼ 0.79-2.72), but not the allele frequency, was significantly associated with septic failure of THA. No significant relationship was noted between septic failure and the promoter 221 or codon 52 SNPs.
Four P2RX7 polymorphisms responsible for receptor loss-of-function (LOF) were investigated in 205 patients operated on for severe acetabular osteolysis and THA failure. 25 The authors hypothesized that the LOF of P2RX7 may impair the balance between the osteolytic and osteogenetic process at the bone -prosthesis interface, increasing osteolysis and bone loss. Although the carriers of any investigated P2RX7 LOF variants were moderately over-represented among patients with severe periprosthetic osteolysis (47% of carriers vs. 53% wild-type genotypes) compared with those with mild/no osteolysis (38% of carriers vs. 62% wild-type genotypes), this difference was not statistically significant. Two rare variants associated with complete loss of P2RX7 receptor function were observed only in THA revision patients. The P2RX7 variant causing complete loss-of-function (P2RX7 568Asn, 307Gln and rs35933842 null allele) were over-represented in 15 of 157 revised (9.6%) and in one of 48 (2.1%) unrevised prosthesis (P ¼ 0.09).
Wedemeyer et al. 26 investigated the possible influence of the functional BCL2 (-938C!A) and CALCA (-1786T!C) polymorphisms in 87 patients with aseptic loosened hip arthroplasties. In normal tissues, the proteins of the Bcl-2 family regulate proliferation and apoptosis 27 by blocking or accelerating it. 28 Bcl-2 itself is an inhibitor of apoptotic cell death, and can act as an anti-apoptotic and anti-proliferative factors. 29 The BCL2 gene has two promoters, P1 and P2. The activated promoter P2 decreases the activity of the other promoter P1, with negative effect on P1 activity. 30 The common single nucleotide polymorphism (SNP, -938C!A (rs 2279115)) in the inhibitory P2 promoter of the BCL2 gene alters the P2 and P1 promoter activities. 31 Alpha-CGRP is a neurotransmitter involved in bone remodelling. 32 The CALCA gene encodes both alpha-CGRP and Calcitionin. These polymorphisms are neither associated with the prognosis of THA nor influence the time to aseptic loosening.
Genetic susceptibility to aseptic loosening
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In a case -control study, Malik et al. 33 investigated 312 Caucasian English patients who had undergone a cemented THA. The patients were divided into three groups: the study groups consisted of 91 patients with early aseptic loosening and 71 patients with deep infection, the control group consisted of 150 patients with clinically and radiological well-fixed THAs. OPG-163 A allele promoter, RANK þ 575 C/T allele, OPG-245 and OPG þ 1181were isolated and amplified. The RANK/RANKL/OPG system is directly implicated in the development of osteolysis around THAs. 34 The osteoblasts RANKL binds to osteoclasts RANK, and directly stimulates the differentiation of osteoclast progenitor cells into osteoclasts. OPG acts as a soluble decoy receptor to RANKL and competes with RANK for RANKL binding, blocking osteoclast differentiation. 33 The frequency of the A allele (P ¼ 0.001, OR ¼ 3.76) and homozygous genotype A/A (P ¼ 0.001) for the OPG-163 SNP were highly associated with aseptic failure compared with the controls. The RANK þ 575 C/T SNP T allele (P ¼ 0.004, OR ¼ 1.77) and T/T genotype (P ¼ 0.008) frequencies were associated with aseptic failure. OPG-245 and OPG þ 1181 SNPs were not significantly associated with aseptic loosening. Compared with the patients in the control group, the patients in the septic group had a significantly higher frequency of the A allele (P ¼ 0.001, OR ¼ 3.42, 95% CI ¼ 1.98-5.91) and homozygous genotype A/A (P ¼ 0.001) for the OPG-163 SNP, with no statistically significant differences for the OPG-245, OPG þ 1181 and RANK þ 575 SNPs.
Cytokines
In a case -control study on 205 Czech Caucasian patients, Gallo et al.
35 investigated 22 SNPs in 13 genes encoding inflammatory cytokines and cytokine receptors (IL-1a, IL-1b, IL-1R, IL-1Ra, IL-4Ra, IL-12, IFN-g, transforming growth factor-b (TGF-b), TNF-a, IL-2, IL-4, IL-6 and IL-10). According to the Saleh radiographic scale, 36 89 patients presented mild osteolysis and 116 presented severe osteolysis. The TNF-238 A allele, higher in the patients with severe than in those with mild osteolysis (OR ¼ 6.59, P ¼ 0.005, PAR ¼ 5.2%), was associated with severe acetabular osteolysis and risk for premature failure, in contrast to the TNF-238 GG genotype. Compared with the GG genotype patients, the TNF-238 A carriers were six times more prone to develop severe osteolysis and had increased cumulative hazard of THA failure (P ¼ 0.024). However, the TNF-238 A allele occurs rarely in patients who exhibit no evidence of osteolysis. The IL6-174G allele, an IL6 gene promoter SNP, was over-represented among patients with severe osteolysis compared with those with mild osteolysis (OR ¼ 2.51, P ¼ 0.007, PAR ¼ 31.5%). Although univariate and multivariate analyses revealed increased risk of severe osteolysis, the presence of the IL6-174G allele in THA patients did not change the cumulative hazard of THA failure. Instead, IL2-330G allele was under-represented in patients with severe osteolysis than in those with mild osteolysis (OR ¼ 0.55, P ¼ 0.043), appearing to protect against severe osteolysis. This protective function was further demonstrated by a lower cumulative hazard of failure of the arthroplasty in carriers compared with noncarriers (P ¼ 0.019).
In a study on 481 patients, Wilkinson et al. 37 investigated two SNPs in the promoter region of TNF, namely TNF-238 and TNF-308. Patients were included in the control and osteolysis groups according to the radiographic criteria of Harris and McGann 38 and Harris and Penenberg. 39 The frequency of the TNF-238A allele was higher in the osteolysis group than in the THA controls (P ¼ 0.05) and the local background population (P ¼ 0.001), and highest in subjects with both femoral and pelvic osteolysis. No difference in allele frequency was observed comparing subjects with unilateral and bilateral osteolysis (P . 0.05). The frequency of the TNF 308A allele was similar in THA subjects (P . 0.05 for all comparisons), with no difference compared with the local background population (P . 0.05).
Common polymorphisms in the genes encoding the pro-inflammatory IL-1 and IL-6 family cytokines were isolated in 612 patients at an average follow-up of 17 years after implantation of a THA. 40 According to Harris and Mc-Gann 38 and Harris and Penenberg 39 radiographic criteria, 272 patients were included in the osteolysis group, and 340 in the control group of patients who showed no evidence of osteolysis on plain antero-posterior and lateral radiographs. The IL1RA þ 2018C (SNP rs419598) allele was underrepresented in the osteolysis group compared with the control group (P ¼ 0.01 by chi-square test) with OR for osteolysis of 0.66 (95% CI: 0.48 -0.91) (P ¼ 0.012). Compared with the TT genotype, the CC genotype was associated with increased IL-1Ra mRNA production in response to PBMC stimulation. On the other hand, no significant differences in genotype or OR were observed between the THA groups for the remaining IL1 or IL6 SNPs (P . 0.05). The haplotype assessment revealed a statistically significant association between the rare IL-6 haplothype-174G/-572G/-597A and osteolysis (2.4% in the osteolysis group vs. 0.8% in the control group; P ¼ 0.02). Kolundzic et al.
41
assessed 41 Caucasian Croatian patients at an average follow-up of 15 years after an uncemented THA. SNPs in genes encoding for pro-inflammatory transforming growth factor-b1 (TGF-b1), IL-6 and TNF-a were investigated. IL-6 is a pleiotropic cytokine involved in the bone metabolism regulation and immune response, and is upregulated in the periprosthetic interface loosening membrane. IL6 stimulates osteoclast activity and bone resorption by an indirect mechanism, given the osteoblastic production of downstream effectors such as receptor/ activator of nuclear factor-kb (RANKL). The TGF-b1 signal sequence (29T!C) transitions suggested a higher risk of developing aseptic loosening associated with T/T genotype than T/C or C/C genotypes. The association between aseptic loosening and TNF-a promoter (-308G!A) transition observed in two patients did not allow to evaluate the potential effects of this SNP on prosthesis survival after THA.
Although the IL-6 (-597) and (-572) SNPs did not appear to have a relevant effect on prosthesis survival, the 597 G!A and 572 G!C genotypes were associated with a markedly increased risk of aseptic loosening.
Enzymes
Godoy-Santos et al. 42 studied the frequency of polymorphism of the MMP-1 promoting gene among patients with early aseptic loosening of THA (test group) and among patients who underwent a successful uncemented THA at a long-term follow-up (control group). The allele 2G had a frequency of 20.97% in the control group, and 83.33% in the aseptic loosening group. The genotype 2G/2G was observed in 66.66% of the test group patients, whereas the genotype 1G/1G was found in 67.74% of the control group subjects. Individuals with the allele 2G seemed to present greater propensity for loosening of the implant (P , 0.001). Therefore, the polymorphism of the promoting gene for MMP-1 may be a genetic marker for failure of osteointegration.
In another study on the same population of patients, Malik et al. 43 investigated the role of four common polymorphisms of MMP1, namely MMP1-1(RS5854), MMP1-2 (RS554499), MMP1-3(RS2397776) and MMP1-4. Degradation products of collagen and matrix components are chemotactic for monocytes, and may lead to the accumulation of macrophages in the periprosthetic connective tissues. The vitamin D system contributes to and directly modulates the osteoprotegerin (RANK/RANKL/OPG triad) system, which acts as the primary control over osteoclast differentiation and activation 44 . Therefore, an alteration in the protein product of vitamin D receptor (VDR) may adversely affect the bone response to bacterial challenges in the presence of prosthetic implants and particulate debris. The frequencies of the C allele (P ¼ 0.001; OR ¼ 3.27; 95% CI: 2.21-4.83) and C/ C genotype (P ¼ 0.001) for the MMP1 SNP were associated with aseptic failure when compared with controls. The MMP2, MMP4, IL6-174 or VDR-L SNPs were not significantly related to aseptic loosening. The T allele (P ¼ 0.007; OR ¼ 1.76; 95% CI: 1.16-2.66) and T/T (P ¼ 0.028) genotype for VDR-T were significantly associated with deep infection compared with controls.
STREGA statement
Four 16, 26, 35, 40 of the 11 studies firstly reported a genetic association between a genetic polymorphism and aseptic loosening. All authors provided information on criteria and methods for selection of subsets of participants. Genetic variants and variables likely associated with population stratification (confounding by ethnic origin) were identified in four studies. 26, 35, 40, 42 Laboratory methods, including source and storage of DNA, genotyping methods and platforms, were described in all the studies. No study specified neither described the nature and magnitude of potential biases, whereas the item regarding the effects of treatment could not be applied to any study. Statistical details and information on method of stratification of the examined population were provided in 10 of 11 studies. The item concerning the numbers of individuals in whom genotyping had been attempted and had been successful could not be applied in any study. Information on genotype, numbers of patients and phenotypes for each genotype category were reported in seven studies. 22, 33, 40, 42, 43 Results were adjusted for multiple comparisons in four studies. 16, 37, 40, 41 Results were summarized in five studies. 22, 26, 40, 41, 42 Discussion Pro-inflammatory mediators are implicated in aseptic periprosthetic osteolysis. 7 Individual susceptibility to aseptic loosening after THA is determined by patient-related factors other than demographic characteristics or co-morbidities. There is a genetic susceptibility component in this condition, which is likely to include contributions by many polymorphisms, and genes encoding for cytokines involved in the development of aseptic loosening. 16, 35, 42 According to the reported studies, TNF-238A, IL6-174G allele and IL6 597 G!A and IL6 572 G!C,TGF-b1 29T!T, MBL C!C 550 SNP, MBL codon 54 SNP G!G genotype; polymorphism of GNAS1 393T!T; the OPG-163 A!A, the RANK þ 575 C!T SNP and T!T genotype, and 2G polymorphism in the region of the gene promoting MMP-1 supposedly predispose to aseptic loosening (Table 2) . On the other hand, although the IL1RA-2018C allele is positively associated with IL-1Ra mRNA production and seems to be protective against osteolysis, its role in relation to the IL1RA intron 2 VNTR is unclear. 40 At present, the mechanisms of gene regulation and activation are still unclear, and key elements are yet to be identified. 45, 46 Collectively, these data expand the current paradigm of osteolysis as a predominantly inflammatory process. Nevertheless, two regulators of osteoclast differentiation and activation, RANKL 47, 48 and osteoprotegerin (OPG), 49 have been identified. As part of the inflammation process, genes of cytokines, chemokines, growth factors, cell adhesion molecules and some acute-phase proteins will be turned on, and frequently over-expressed. Part of this genetic regulation is controlled by the nuclear factor kappa B (NFkB), probably involved in the development of osteoclastogenesis. 50, 51 This abnormality occurs as a result of a defect either during osteoclast precursor cell differentiation or during the maturation of osteoclasts. It is possible that the osteoclastogenic activity of several cytokines, such as TNF, IL-1 might be ameliorated by prevention of NF-kB, binding to their respective binding sites of the promoter sequence. Even though the regulation of NF-kB activation could represent a therapeutic strategy for reducing inflammatory tissue damage, a complete and persistent blockage of NF-kB activation could lead to immune deficiency, up to cell death. 50 All these data come from single-centre studies. If these single-centre findings are replicated in other centres and populations, new avenues will open for pre-surgical genetic testing and also to investigate immune response modulation in THA. Therefore, although the findings supported the role of SNPs genotypes in aseptic loosening, further multi-centre prospective studies are necessary to confirm the general validity of the findings reported. Additionally, other genes and genetic polymorphisms could play a major role in the interaction of biomaterials and the environment. Therefore, research in this field could lead to better understanding of mechanisms of aseptic loosening and improve the results of THA.
Even though the STREGA assessment could not be fully applied, similar limitations concerning population stratification, description of the nature and magnitude of potential biases, and adjustment for multiple comparisons have been found in almost all studies. Genetic association studies have introduced new data, but the likelihood of very small individual effects, including inadequate reporting of results, even from well-conducted studies, hampers assessment of a study's strengths and weaknesses, and hence the integration of evidence. 52, 53 For the future, studies on associations between genetics and pathological aspects should keep to the STREGA statement. These recommendations do not aim to prescribe or dictate how a genetic association study should be designed, but to improve the transparency of their reporting, regardless of choices made during design, conduct or analysis.
Conclusion
Several gene pathways and genes contribute to the genetic susceptibility to aseptic loosening following THA. Association studies can be very helpful to clarify the linkage between complex disease phenotype and specific genotype. Prospective studies with larger samples are required to improve the strength of the studies. Genetic studies in the field of aseptic loosening will further enhance the understanding of prosthesis failure, and may inform and direct pharmaceutical interventions. The goal would be to ascertain whether and how a given genotype can be related to the phenotype 'failure of THA'. This target would influence clinical practice, allowing better planning and anticipating the need for early intervention.
